A new trading day began on Monday, with Akebia Therapeutics Inc (NASDAQ: AKBA) stock price up 0.52% from the previous day of trading, before settling in for the closing price of $1.91. AKBA’s price has ranged from $0.80 to $2.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -10.63%. Meanwhile, its annual earnings per share averaged 33.33%. With a float of $250.51 million, this company’s outstanding shares have now reached $261.23 million.
Let’s determine the extent of company efficiency that accounts for 181 employees. In terms of profitability, gross margin is 60.08%, operating margin of -31.47%, and the pretax margin is -43.33%.
Akebia Therapeutics Inc (AKBA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc is 4.10%, while institutional ownership is 23.98%. The most recent insider transaction that took place on Mar 03 ’25, was worth 84,928. In this transaction CEO and President of this company sold 46,409 shares at a rate of $1.83, taking the stock ownership to the 2,557,921 shares. Before that another transaction happened on Mar 03 ’25, when Company’s SVP, Chief Medical Officer sold 7,144 for $1.83, making the entire transaction worth $13,074. This insider now owns 809,090 shares in total.
Akebia Therapeutics Inc (AKBA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.33% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Here are Akebia Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.33, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.04 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Looking closely at Akebia Therapeutics Inc (NASDAQ: AKBA), its last 5-days average volume was 4.1 million, which is a jump from its year-to-date volume of 3.51 million. As of the previous 9 days, the stock’s Stochastic %D was 5.15%. Additionally, its Average True Range was 0.18.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 28.94%, which indicates a significant increase from 28.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 206.38% in the past 14 days, which was higher than the 91.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0749, while its 200-day Moving Average is $1.6550. However, in the short run, Akebia Therapeutics Inc’s stock first resistance to watch stands at $1.9633. Second resistance stands at $2.0067. The third major resistance level sits at $2.0733. If the price goes on to break the first support level at $1.8533, it is likely to go to the next support level at $1.7867. Should the price break the second support level, the third support level stands at $1.7433.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
With a market capitalization of 501.56 million, the company has a total of 236,231K Shares Outstanding. Currently, annual sales are 160,180 K while annual income is -69,410 K. The company’s previous quarter sales were 46,500 K while its latest quarter income was -22,800 K.
